We are live on ! Find out more
FC

Finepoint Capital Portfolio holdings

AUM $1.95B
1-Year Est. Return 45.61%
This Fund
S&P 500
This Quarter Est. Return
+16.54%
1 Year Est. Return
+45.61%
3 Year Est. Return
+24.83%
5 Year Est. Return
+26.66%
10 Year Est. Return
–
AUM
$304M
AUM Growth
+$14.8M
Cap. Flow
-$12.3M
Cap. Flow %
-4.05%
Top 10 Hldgs %
63.35%
Holding
64
New
3
Increased
5
Reduced
7
Closed
7

Top Buys

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$19.4M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$16M
3
TVTX icon
Travere Therapeutics
TVTX
+$11.5M
4
SWTX
SpringWorks Therapeutics
SWTX
+$8.83M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$7.22M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$15.8M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$15.1M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$14.1M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$12.1M
5
ARGX icon
argenx
ARGX
+$8.9M

Sector Composition

Rank Sector Weight
1 Healthcare 86.74%
2 Materials 7.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVTX icon
1
Travere Therapeutics
TVTX
$5.27B
$25.4M 8.34%
1,028,875
+444,575
+76% +$11.5M
ASTL icon
2
Algoma Steel
ASTL
$404M
$23.9M 7.87%
3,716,732
– –
PRTA icon
3
Prothena Corp
PRTA
$453M
$18.5M 6.09%
305,400
-152,100
-33% -$4.81M
CYTK icon
4
Cytokinetics
CYTK
$10.9B
$18.4M 6.07%
380,793
-38,640
-9% -$1.86M
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.38B
$18.2M 5.98%
1,111,030
+403,830
+57% +$6.54M
APLS
6
DELISTED
Apellis Pharmaceuticals
APLS
$18.2M 5.98%
266,090
-52,310
-16% -$3.1M
ARVN icon
7
Arvinas
ARVN
$517M
$17.8M 5.84%
+399,000
New +$19.4M
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$17.7M 5.83%
987,600
– –
FOLD
9
DELISTED
Amicus Therapeutics
FOLD
$17.6M 5.8%
1,688,400
-322,500
-16% -$3.59M
RCUS icon
10
Arcus Biosciences
RCUS
$3.44B
$16.9M 5.56%
646,586
+111,586
+21% +$2.95M
SAGE
11
DELISTED
Sage Therapeutics
SAGE
$16.8M 5.53%
429,313
-46,287
-10% -$1.79M
LKFT
12
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$16.2M 5.32%
379,702
+120,302
+46% +$6.16M
IOVA icon
13
Iovance Biotherapeutics
IOVA
$2.23B
$15.2M 5%
1,586,043
+625,843
+65% +$7.22M
CERE
14
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$15.2M 4.99%
+536,901
New +$16M
ASND icon
15
Ascendis Pharma A/S
ASND
$17.1B
$12.7M 4.19%
123,400
-36,100
-23% -$3.42M
ARGX icon
16
argenx
ARGX
$53.8B
$10.2M 3.34%
28,770
-24,030
-46% -$8.9M
SWTX
17
DELISTED
SpringWorks Therapeutics
SWTX
$8.79M 2.89%
+308,092
New +$8.83M
GBTG.WS
18
DELISTED
Global Business Travel Group, Inc. Warrants, each exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share
GBTG.WS
$1.43M 0.47%
913,000
– –
BTWNW
19
DELISTED
Bridgetown Holdings Limited Warrants
BTWNW
$116K 0.04%
895,000
– –
ZTAQW
20
DELISTED
Zimmer Energy Transition Acquisition Corp. Warrants
ZTAQW
$111K 0.04%
358,270
– –
CPAAW
21
DELISTED
Conyers Park III Acquisition Corp. Warrants
CPAAW
$104K 0.03%
571,666
– –
STRY.WS
22
DELISTED
Starry Group Holdings, Inc. Warrants, each whole warrant exercisable to purchase 1.2415 shares of Class A common stock at an exercise price of $11.50 per 1.2415 shares of Class A common stock
STRY.WS
$87K 0.03%
669,000
– –
CNDA.WS
23
DELISTED
Concord Acquisition Corp II Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50
CNDA.WS
$86K 0.03%
408,333
– –
CCVI.WS
24
DELISTED
Churchill Capital Corp VI Warrants, each exercisable for one share of Class A common stock at an exercise price of $11.50 per share
CCVI.WS
$76K 0.03%
540,000
– –
CVIIW
25
DELISTED
Churchill Capital Corp VII Warrants
CVIIW
$74K 0.02%
548,000
– –
1
2 3

Similar funds

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return

Finepoint Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Finepoint Capital held 64 positions worth $304M, up 5.1% from $289M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Finepoint Capital withdrew a net $12.3M in Q3 2022, closing 7 positions and reducing 7 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $15.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 87% a quarter earlier, followed by Materials.

Against the trend, Finepoint Capital opened a new position in Arvinas worth $17.8M.

  • Finepoint Capital's largest Q3 2022 buy was Arvinas: 399,000 shares worth $17.8M.
  • Finepoint Capital added most to Travere Therapeutics in Q3 2022, an estimated $11.5M increase.
  • Finepoint Capital's biggest Q3 2022 reduction was argenx, cutting an estimated $8.9M.
  • Finepoint Capital fully exited Sarepta Therapeutics in Q3 2022, selling an estimated $15.8M.
  • Finepoint Capital's ten largest holdings make up 63% of its $304M portfolio in Q3 2022.
  • Finepoint Capital opened 3 new positions and closed 7 in Q3 2022.
  • Finepoint Capital's portfolio value rose 5.1% quarter-over-quarter to $304M.

Based on Finepoint Capital's 13F filing for Q3 2022, filed 10 Nov 2022.